The healthcare sector saw a major bump for two small cap biopharmaceutical companies today, both building on major gains from last week. Omeros Corp. (OMER) shot up over 35 percent, continuing a run that’s seen the company’s shares jump almost 85 percent since last Monday. Joining Omeros was Geron Corporation (GERN) , which was up over 20 percent in early trading and has more than doubled its share price this month.
Omeros corporation’s strong Monday comes one week after it shot up 68.17 percent in on day on an upgrade from Wedbush that increased its price target to $28, a price that would represent a 460 percent jump from its closing price the Friday prior. Wedbush analyst Liana Moussatos cited eye-surgery drug OMS302 as the primary reason for her improved outlook on Omeros, but the company also announced Thursday that it was initiating a new mid-stage trial for its schizophrenia drug OMS824. Today’s gains pushed Omeros past resistance, showing considerable optimism for the company on the part of investors.
On Sept. 11 Geron President and CEO John Scarlett, M.D., presented at the Stifel conference, and it must have been one great presentation, because shares are up over 80 percent since then. A deeper look, though, may reveal that Geron’s recent gains come off of optimism on the part of investors because of action on the options market. The day after the presentation at the Stifel conference, 10,000 put options were sold with a strike price of $2, which could have sparked the increased interest by those traders who closely watch the options market. Geron currently has one phase-2 drug clinical trial currently in motion for its drug imetelstat. This study is focused on imetelstat as a treatment for essential thrombocythemia or polycythemia vera.